Trinity Delta Lighthouse: Bonesupport
Trinity Delta view: Bonesupport is continuing to make excellent progress, with the FDA’s “breakthrough device†designation for CERAMENT G being the latest example. The focus on commercial execution is paying off, with global sales clearly gaining momentum. It is the restructured, and increasingly proven, US commercial platform (post-Zimmer Biomet termination) that will now launch CERAMENT G as early as 2021. Also, we believe FDA approval remains the de facto “gold standard†and that it could impart a “halo†effect to sales in existing European markets. Our valuation for Bonesupport is SEK2.27bn or SEK43.3/share.Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.